<code id='505AAAA749'></code><style id='505AAAA749'></style>
    • <acronym id='505AAAA749'></acronym>
      <center id='505AAAA749'><center id='505AAAA749'><tfoot id='505AAAA749'></tfoot></center><abbr id='505AAAA749'><dir id='505AAAA749'><tfoot id='505AAAA749'></tfoot><noframes id='505AAAA749'>

    • <optgroup id='505AAAA749'><strike id='505AAAA749'><sup id='505AAAA749'></sup></strike><code id='505AAAA749'></code></optgroup>
        1. <b id='505AAAA749'><label id='505AAAA749'><select id='505AAAA749'><dt id='505AAAA749'><span id='505AAAA749'></span></dt></select></label></b><u id='505AAAA749'></u>
          <i id='505AAAA749'><strike id='505AAAA749'><tt id='505AAAA749'><pre id='505AAAA749'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:5698
          Photography of the US department of health and human services in Silver Spring MD
          Manuel Balce Ceneta/AP

          An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

          Triple-check your data or we’ll reject your device, the FDA warned.

          advertisement

          The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Sen. Paul opposes bill to ban Chinese biotechs
          Sen. Paul opposes bill to ban Chinese biotechs

          Sen.RandPaul(R-Ky.)WinMcNamee/GettyImagesWASHINGTON—ASenatepanelWednesdaypassedabillaimedatpreventin

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          With psoriasis trial ahead, Alumis raises $259 million

          Aclose-upofpsoriasisonahand.AdobeSanFranciscostartupAlumisInc.hasraised$259millioninabidtobestbigpha